Introduction {#sec1}
============

Despite the gradual development of gastric cancer (GC) screening programs, most of the patients with GC are still diagnosed in advanced stages, with a 5-year survival rate of only 10% \[[@cit0001]\].

The name "early gastric cancer" (EGC) suggests a localized tumor with a potential for complete cure after complete resection, i.e., a low risk of lymph node metastases \[[@cit0002], [@cit0003]\]. For EGCs, endoscopic mucosal resection (EMR) is preferred for non-metastatic intramucosal differentiated carcinomas smaller than 2 cm, with a protruded aspect at the endoscopic examination. If the tumor is ulcerated, EMR is recommended for differentiated carcinomas smaller than 1 cm, whereas endoscopic submucosal dissection (ESD) is indicated for larger non-metastatic tumors with invasion limited to the submucosa \[[@cit0004], [@cit0005]\]. The European criteria used for the endoscopic resection of EGC or surgery were outlined in the Paris endoscopic classification of superficial neoplastic gastrointestinal lesions published in 2003 \[[@cit0006]\]. However, although EMR and ESD are performed in some European medical institutes, open gastrectomy is mostly considered a standard therapy for any stage of GC, including EGCs \[[@cit0004], [@cit0007]\]. Long-term follow-up is necessary to examine the potential benefits of EMR/ESD vs. gastrectomy, as well as extension of lymph node dissection.

In this article, the prognostic value of some clinicopathologic factors and immunohistochemical (IHC) features are explored in patients with surgically removed EGCs diagnosed in three medical centers in Romania, Poland, and Hungary. Based on our own experience and literature data, an EGC-adapted staging system is proposed.

Material and methods {#sec2}
====================

Patients and tissue samples {#sec2.1}
---------------------------

The surgically removed GC cases were retrospectively collected from three medical centers in Europe: the Clinical County Emergency Hospital of Tirgu-Mures, Romania and two Institutes of Oncology -- Warsaw, Poland and Budapest, Hungary. The IHC stains were performed on the paraffin blocks collected at the Department of Pathology of the University of Medicine and Pharmacy of Tirgu-Mures, Romania. The head of the three departments approved the processing of the cases, and the approval of the Ethical Committee of the University of Medicine and Pharmacy of Tirgu-Mures, Romania, was obtained.

The clinicopathological and IHC features of EGC were retrospectively evaluated in 29 EGCs selected from 338 GC (8.5%) patients who underwent partial or total gastrectomy with lymph node dissection. This material included the 338 consecutive case series from the three medical centers, with a median follow-up time of 36 months (range: 2--61 months). From these cases, we selected all consecutive patients diagnosed postoperatively with EGC. All of the cases were surgical specimens; biopsy specimens were not taken into account. Patients who died in the first month after surgery were not included in this case series.

For tumor staging, the WHO/AJCC staging system (2010) was used, based on the invasion of the mucosa (pT1a) and submucosa (pT1b) \[[@cit0002], [@cit0003]\], and a sub-classification was done based on Japanese rules, with sub-categorizing in pT1a-m1 (invasion of upper third of mucosa), pT1a-m2 (middle third of mucosa), pT1a-m3 (lower third of mucosa), pT1b-sm1 (upper third of submucosa), pT1b-sm2 (middle third of submucosa), and pT1b-sm3 (lower third of submucosa) \[[@cit0004]\].

Although histopathological diagnoses were performed according to the WHO 2010 classification \[[@cit0002], [@cit0003]\], from the category of "poorly cohesive carcinoma", those with features of "signet ring cell carcinoma" were listed as a separate subtype. To certify the presence of mucinous carcinomas or a mucinous component, PAS/alcian blue staining was performed for all of the cases.

All of the metastases were biopsy proven. In lymph node negative cases, 5 sections were performed for any sentinel lymph node.

The IHC stains were performed using the antibodies mentioned in [Table I](#t0001){ref-type="table"} and the Novolink Polymer Detection System (Novocastra, Newcastle Upon Tyne, UK) according to the instructions of the manufacturer. The developing was done with DAB (diaminobenzidine) solution (Novocastra). For the negative controls, incubation was done with the omission of specific antibodies. The IHC assessment was performed by two pathologists using the criteria described previously in the literature \[[@cit0008]\]. Microvessel density (MVD) was measured with CD31 and CD105, using the image analysis software ImageJ (NIH); the percentage of positive endothelial area versus the total area of the microscopic field was determined \[[@cit0008]\].

###### 

Immunohistochemical antibodies used in the study

  -------------------------------------------------------------------
  Antibody (company)                  Clone                Dilution
  ----------------------------------- -------------------- ----------
  p53 (LabVision, Fremont, CA, USA)   DO-7                 RTU

  Ki67 (LabVision)                    SP6                  RTU

  CD31/PECAM-1 (LabVision)            JC/70A               1 : 25

  CD105/endoglin (Novocastra)         Mouse monoclonal     1 : 25

  VEGF-A (LabVision)                  VG1                  1 : 50

  COX-2 (Novocastra)                  Monoclonal           1 : 100

  HER-2 (Dako Glostrup, Denmark)      5A2\                 1 : 1000
                                      cerbB2-oncoprotein   

  MLH-1 (Novocastra)                  ES05                 1 : 100

  MSH-2 (Novocastra)                  25D12                1 : 50

  E-cadherin (Dako)                   NCH-38               1 : 50

  Vimentin (Dako)                     V9                   1 : 800
  -------------------------------------------------------------------

RTU -- ready to use.

Statistical analysis {#sec2.2}
--------------------

Statistical analysis was done with the Graph-Pad InStat 3 software and two-sided tests. A *p*-value \< 0.05 with 95% confidence interval was considered statistically significant. The patients' characteristics and IHC descriptions were presented using descriptive statistics. The results were presented using the mean value or were expressed as mean ± standard deviation. The univariate analysis was performed with Pearson's or Student's *t-*test. For multiple associations the Fisher exact test was used, and the correlations between two variables were performed using the Mann-Whitney test. Multivariate logistic regression analysis and the log-rank test were used to evaluate the independent prognostic factors. Tumor-related death was used to explore the overall survival rate.

Results {#sec3}
=======

Clinicopathological characteristics {#sec3.1}
-----------------------------------

As mentioned, the 29 patients with EGCs were selected from 338 GC (8.5%) patients diagnosed in the three European institutes. In Romania, they represented 5.61% of all GCs (11 patients with EGCs from a total of 196 GCs), whereas in Poland and Hungary the percentage was higher, constituting 12.37% (12 EGCs from a total of 97 GCs) and 13.33% (6 EGCs from a total of 45 GCs) respectively.

Examining the 29 patients with EGCs, a male predominance was noted, with a male/female ratio of 1.6 : 1 (18 males and 11 females). Independently from the patient's geographic origin, males were diagnosed at a significantly younger age (mean age: 58.61 ±10.05 years; range: 36--75 years) than the females (mean age: 67.18 ±11.71 years; range: 42--80 years) (*p* = 0.04) ([Table II](#t0002){ref-type="table"}).

###### 

Clinicopathological characteristics of patients with early gastric cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No. of case   Clinical institution   Gender   Age \[years\]   Location   Macro[\*](#tf2-1){ref-type="table-fn"}   Tumor size \[cm\]   Histology       Angio-lymphatic invasion   pT   Japanese pT[\*\*](#tf2-2){ref-type="table-fn"}   pN   Dissected LNs (*n*)   pM   Intestinal metaplasia   Overall survival[\*\*\*](#tf2-3){ref-type="table-fn"} \[months\]   Familial history -- tumors
  ------------- ---------------------- -------- --------------- ---------- ---------------------------------------- ------------------- --------------- -------------------------- ---- ------------------------------------------------ ---- --------------------- ---- ----------------------- ------------------------------------------------------------------ -----------------------------------------------------
  1             Romania                F        64              Antrum     III                                      4                   Sig             No                         1b   Sm-1                                             0    23                    0    Yes                     Alive                                                              No

  2             Romania                F        73              Antrum     III                                      5                   G2              No                         1b   Sm-1                                             0    34                    0    Yes                     Alive                                                              No

  3             Romania                M        62              Diffuse    I                                        6                   G2              No                         1b   Sm-1                                             0    31                    0    Yes                     Alive                                                              No

  4             Romania                F        70              Antrum     III                                      2.7                 G2              No                         1b   Sm-2                                             0    15                    0    No                      Alive                                                              No

  5             Romania                M        66              Antrum     I                                        3                   G3              No                         1b   Sm-2                                             0    12                    0    Yes                     Alive                                                              No

  6             Romania                M        66              Antrum     III                                      0.5                 G2              No                         1b   Sm-3                                             0    23                    0    Yes                     Alive                                                              No

  7             Romania                M        45              Antrum     IIa                                      2                   Sig             No                         1b   Sm-2                                             0    32                    0    No                      Alive                                                              No

  8             Romania                F        74              Antrum     III                                      2.5                 G2              Yes                        1b   Sm-2                                             0    42                    1    Yes                     Alive                                                              No

  9             Romania                M        54              Antrum     IIa                                      8                   G2              Yes                        1b   Sm-1                                             3    46                    1    Yes                     14                                                                 Father -- gastric cancer;\
                                                                                                                                                                                                                                                                                                                                                                    First cousin -- signet-ring cell carcinoma -- colon

  10            Romania                M        64              Antrum     IIa                                      6                   Sig             Yes                        1a   M-3                                              3    32                    1    No                      2                                                                  No

  11            Romania                M        75              Proximal   I                                        0.5                 G2              No                         1b   Sm-2                                             0    23                    0    No                      Alive                                                              No

  12            Poland                 M        70              Antrum     IIc                                      4                   Muc             No                         1b   Sm-1                                             0    21                    0    Yes                     Alive                                                              Father -- gastric cancer

  13            Poland                 F        42              Antrum     IIc                                      1.4                 Poor            No                         1a   M-2                                              0    26                    0    No                      Alive                                                              Father -- prostate cancer

  14            Poland                 M        64              Proximal   IIc                                      2                   Muc             No                         1b   Sm-1                                             0    23                    0    No                      Alive                                                              No

  15            Poland                 M        49              Proximal   IIc                                      1.7                 G3              No                         1b   Sm-1                                             0    22                    0    No                      Alive                                                              Father -- gastric cancer

  16            Poland                 F        62              Proximal   IIc                                      3.7                 G3              No                         1a   M-2                                              0    16                    0    No                      Alive                                                              No

  17            Poland                 M        63              Proximal   IIc                                      1.5                 G2              Yes                        1a   M-3                                              1    16                    0    Yes                     61                                                                 No

  18            Poland                 M        36              Antrum     IIc                                      3                   G2              Yes                        1b   Sm-2                                             2    12                    0    No                      24                                                                 Father -- lung cancer

  19            Poland                 M        67              Proximal   IIc                                      7                   Poor            No                         1b   Sm-1                                             0    14                    0    Yes                     30                                                                 No

  20            Poland                 M        47              Antrum     IIb                                      7.5                 G2              No                         1b   Sm-1                                             0    21                    0    Yes                     Alive                                                              Mother -- breast cancer

  21            Poland                 M        49              Proximal   I                                        9                   G2              No                         1b   Sm-2                                             0    25                    0    No                      35                                                                 No

  22            Poland                 F        51              Proximal   IIc                                      9                   Sig             No                         1a   M-2                                              0    24                    0    No                      Alive                                                              No

  23            Poland                 F        80              Proximal   I                                        2.8                 Papillary cc.   No                         1a   M-2                                              0    23                    0    No                      Alive                                                              No

  24            Hungary                M        62              Antrum     I                                        7                   G2              No                         1b   Sm-1                                             0    11                    0    No                      Alive                                                              No

  25            Hungary                F        72              Antrum     IIa                                      5                   G2              No                         1b   Sm-1                                             0    13                    0    Yes                     Alive                                                              No

  26            Hungary                M        57              Antrum     IIa                                      3.5                 Sig             Yes                        1b   Sm-2                                             3    16                    0    No                      Alive                                                              No

  27            Hungary                F        72              Antrum     IIa                                      4.5                 Sig             No                         1b   Sm-2                                             0    24                    0    No                      Alive                                                              No

  28            Hungary                M        59              Antrum     IIa                                      6                   Sig             No                         1b   Sm-1                                             0    21                    0    No                      Alive                                                              No

  29            Hungary                F        79              Antrum     IIa                                      5                   G3              Yes                        1b   Sm-3                                             2    22                    0    Yes                     Alive                                                              No
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Macroscopic classification according to the criteria proposed by the Japanese Society of Gastroenterology and Endoscopy \[[@cit0002]\] (I -- protruded, IIa -- superficial elevated, IIb -- flat, IIc -- superficial depressed, III -- excavated);

based on the depth of infiltration in mucosa (m1-m3) and submucosa (sm1-3);

follow-up 2-61 months. cc. -- carcinoma, F -- female, G2, G3 -- adenocarcinoma, M -- male, Muc -- mucinous adenocarcinoma, pN -- lymph node metastases, pM -- distant metastases, poor -- poorly cohesive diffuse carcinoma, pT -- tumor depth (1a -- tumor limited to mucosa, 1b -- tumor limited to submucosa), sig -- signet-ring cell carcinoma).

Most of the cases (*n* = 18; 62.07%) were localized in the distal stomach, the proximal stomach being mostly predominant in patients from Poland. The mean tumor size was 4.26 ±2.45 cm (range: 0.5--9 cm).

The signet ring cell subtype was seen in 7 (24.14%) cases, while poorly cohesive non-signet ring cell carcinoma was diagnosed in only 2 patients from Poland, 1 in the proximal stomach and 1 in the antrum (cases no. 13 and 19). Comparing the 7 signet ring cell carcinomas with the intestinal-type adenocarcinomas, no significant differences were seen regarding the mean age (58.85 ±8.97 years (range: 45--72 years) vs. 63.65 ±11.61 years (range: 36--80 years); *p* = 0.33) or other clinicopathologic parameters. Only 6 of the 29 (20.69%) cases were limited to mucosa; 2 of them (cases no. 10 and 17), located in the deep mucosa (pT1a-m3), were metastatic ([Table II](#t0002){ref-type="table"}).

Seven out of the 29 (24.14%) patients presented angio-lymphatic invasion, 6 of them also having metastases in the regional lymph nodes. Regarding the distant metastases, 2 patients (cases no. 9 and 10) had liver metastases, whereas case no. 8 had a skip metastasis in the non-regional lymph node located along the middle colic artery (station 15) \[[@cit0009]\]. The first patient with multicentric liver metastasis (case no. 9) had a multifocal adenocarcinoma with minute submucosal invasion (pT1b-sm1). He was postoperatively treated with chemotherapeutics and hepatic chemoembolization and died at 14 months of follow-up. The second patient (case no. 10) presented a multifocal signet ring cell carcinoma limited to the mucosa (pT1a-m3), without invasion of the muscularis mucosae, but extensive intramural carcinomatosis of the lymph vessels located in the submucosa, muscularis, and serosa was noted ([Figure 1](#f0001){ref-type="fig"}). This aspect was associated with metastases in all of the 48 regional D2-lymph nodes and 1 liver metastasis that were surgically removed. With chemotherapy, the patient is still alive at the 6^th^ month of follow-up. The third patient (case no. 8) presented a pT1b-sm2 staged adenocarcinoma and was postoperatively treated with chemotherapy. She is alive at the 10^th^ month of follow-up.

![In a gastric cancer with direct invasion limited to the deep mucosa (pT1a-m3), extensive intramural carcinomatosis of the lymph vessels can be noted in blue in the submucosa muscularis propria, and subserosa (case 10), with PAS/alcian stain (A) and in brown with E-cadherin (B)](AMS-13-27147-g001){#f0001}

Immunohistochemistry {#sec3.2}
--------------------

In all of the 29 cases, investigation of the possible prognostic value of the positive E-cadherin, HER-2, p53, Ki67, VEGF-A (vascular endothelial growth factor), and COX-2 was performed. The mean MVD value was 3.11 ±1.23 for CD31 and 2.61 ±1.56 for CD105, without a correlation between the two endothelial markers (*p* = 0.18). VEGF-A positivity was seen in 15 (51.72%) of the 29 cases but was not correlated with MVD for either CD31 (*p* = 0.26) or CD105 (*p* = 0.83). COX-2 positivity was observed in 14 (48.27%) cases, without a correlation with VEGF positivity. The MVD counted with CD31 was significantly higher in COX-2 positive vs. COX-2 negative cases (4.15 ±0.24 vs. 2.14 ±0.11; *p* \< 0.0001). A positive correlation was also found between COX-2 and CD105 (3.46 ±0.47 vs. 1.82 ±0.19; *p* = 0.03).

HER-2 positivity (+++) was observed in only 6 (20.69%) of the 29 cases: 1 mucinous adenocarcinoma (case no. 14), 2 signet ring cell carcinomas (cases no. 1 and 7), and 3 moderately differentiated adenocarcinomas (cases no. 2, 6, and 11). None of the 6 cases presented metastases. Meanwhile, all of them expressed VEGF and COX-2 and presented p53 and Ki67 positivity. MVD was significant higher in the HER-2 positive compared with HER-2 negative cases ([Figure 2](#f0002){ref-type="fig"}), for both CD31 (4.36 ±0.4 vs. 2.78 ±0.22; *p* = 0.03) and CD105 (4.04 ±0.54 vs. 2.24 ±0.29; *p* = 0.0007).

![In an intestinal-type carcinoma that showed HER-2 positivity (A) the microvessel density is relatively high (B), compared with a HER-2 negative diffuse gastric cancer (C)](AMS-13-27147-g002){#f0002}

Positivity for p53 and Ki67 was observed in 16 (55.17%) and 14 (48.27%) cases respectively. Two of the 4 tumors of the gastroesophageal junction (GEJ) expressed COX-2 and were Ki67/p53 negative (cases no. 16 and 23). Both of the patients are still alive after 22 months of follow-up. The other two COX-2 negative/p53 negative/Ki67 positive EGCs of the GEJ patients presented associated intestinal metaplasia (cases no. 17 and 19) and died at 61 and 30 months respectively. None of the 29 cases expressed vimentin, and all of them showed positivity for both markers of microsatellite status, MLH-1 and MSH-2. E-cadherin was totally lost in case no. 7 (a 45-year-old man with a pT1b-sm2 signet ring cell carcinoma without a familial history of any neoplasia), the other cases being positive ([Figure 1](#f0001){ref-type="fig"}).

Overall survival rate {#sec3.3}
---------------------

None of the 29 patients presented local recurrence. Six (20.69%) out of the 29 patients died at a median time of 27 months after surgery (ranging between 2 and 61 months) ([Table II](#t0002){ref-type="table"}). All of these tumors were negative for p53 and HER-2.

Only tumor localization was proved to have independent prognostic value (*p* = 0.03, χ^2^ = 6.44, degrees of freedom (DF) = 2) among all of the analyzed parameters. The longest survival was noted for antral EGC patients, while the proximal localization proved to be associated with the lowest survival rate, independently from other parameters. Slightly longer survival was also found in females, regardless of age, compared with males (*p* = 0.04, χ^2^ = 4.30, DF = 1) ([Figure 3](#f0003){ref-type="fig"}). When the pT1a cases were analyzed, the subdivision into m1, m2 and m3 did not prove to have prognostic value, and nor did pT1b subdivision into sm1, sm2 and sm3. Moreover, it was difficult to separate m2 from m3 and sm2 from sm3.

![In patients with early gastric cancer, the overall survival rate is directly correlated with patient's gender (A) and tumor localization (B) but does not depend on the lymph node status (C), distant metastases (D), or any of the following immunohistochemical markers: COX-2 (E), VEGF-A (F) HER-2 (G), and Ki67 (H)\
AN -- antrum, EGJ -- esophagogastric junction, N -- lymph node status, M -- distant metastases, P -- proximal, 1 -- positive immunostain, 2 -- negative stain.](AMS-13-27147-g003){#f0003}

There was no correlation between the overall survival rate and any of the following immunohistochemical markers: Ki-67 (*p* = 0.39, χ^2^ = 0.72, DF = 1), p53 (*p* = 0.26, χ^2^ = 1.22, DF = 1), HER-2 (*p* = 0.23, χ^2^ = 1.43, DF = 1), COX-2 (*p* = 0.66, χ^2^ = 0.18, DF = 1), and VEGF (*p* = 0.35, χ^2^ = 0.83, DF = 1) ([Figure 3](#f0003){ref-type="fig"}).

Discussion {#sec4}
==========

The lack of GC screening programs leads to the diagnosis of less than 15% of tumors in their early stages in Europe \[[@cit0007]\], including Poland and Hungary (12% and 13% of all GCs) and even a lower percentage in Romania (5.6%), as demonstrated in the present report. In contrast, the proportion of EGC is much higher, up to 40--50% of all GCs in Japan and South Korea \[[@cit0004], [@cit0005], [@cit0010], [@cit0011]\].

Although about 24% of EGCs have a signetring cell subtype in European patients (24.14% (*n* = 7) in our material), the histological variant seems to not influence the 3-year survival rate in the pT1 stage \[[@cit0012]\]. In larger cohorts but not in our group of patients, it was proved that the signet ring cell carcinomas, compared to the non-signet ring cell subtypes, occur in younger patients, and the submucosa is more frequently involved. There is a disagreement concerning the number of invaded lymph nodes and the relapse rate, if they are independent from the histologic subtype \[[@cit0012]\] or higher in signet ring cell carcinomas \[[@cit0005]\]. In Japanese patients with EGC, about 15% of the cases were proved to be signet ring cell carcinomas, and their prognosis was significantly worse compared to the non-signet ring cell variants \[[@cit0010]\].

Despite the several studied parameters, age and pTNM stage remain the most important independent factors for predicting the survival of patients with EGC \[[@cit0010], [@cit0013]--[@cit0016]\]. In our material, the lymph node metastatic rate was 20.69%. Only 2 of the 6 metastatic cases were diagnosed in the pT1a-m3 stage; the others were T1b-staged. This rate was higher than most of the previously published studies, which revealed lymph node positivity in less than 10% of the cases; 3--4% for pT1a and 17--20% for pT1b carcinomas \[[@cit0004], [@cit0005], [@cit0013]\]. The independent predictive risk factors for lymph node involvement are the depth of infiltration (pT1a-m3 and pT1b stages), presence of angiolymphatic invasion, ulceration, tumor size larger than 2--3.5 cm, undifferentiated histology, and expression of epidermal growth factor receptor (EGFR) \[[@cit0002], [@cit0005], [@cit0013]--[@cit0016]\]. However, grouping of the cases based on one third of the mucosa or of the submucosa is very difficult. Moreover, because m3 and sm3 were mostly shown to have prognostic value, compared with m1/2 and sm1/2 respectively, we consider that grouping in two categories based on the upper and lower part of the mucosa and submucosa, respectively, would be more practical for daily activity ([Table III](#t0003){ref-type="table"}).

###### 

Proposal for an early gastric cancer adapted pTNM staging system based on the currently used WHO/AJCC systems \[[@cit0002], [@cit0003]\], our experience, and criteria from Japanese and European literature \[[@cit0001], [@cit0004]--[@cit0026]\] (the proposed modified criteria are emphasized with bold + italic; these criteria are not available for advanced tumors, currently classified as pT2--T4)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                            Significance
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Tis                                                  Carcinoma *in situ*: intraepithelial tumor without invasion of the lamina propria

  T1a                                                  Tumor invades lamina propria or muscularis mucosae (m)

  *** T1a-m1***\                                       ***-- Invasion of the upper half of the mucosa***\
  *** T1a-m2***                                        ***-- Invasion of the lower half of the mucosa***

  T1b                                                  Tumor invades submucosa (sm)

  *** T1b-sm1***\                                      ***-- Invasion of the upper half of the submucosa***\
  *** T1b-sm2***                                       ***-- Invasion of the lower half of the submucosa***

  N0                                                   No regional lymph node metastasis

  N1[\*](#tf3-1){ref-type="table-fn"}                  Metastasis in 1--2 regional lymph nodes

  *** N1a***\                                          ***-- Metastasis in 1--2 regional lymph nodes***\
  *** N1b***\                                          ***-- Micrometastasis in 1--2 regional lymph nodes***\
  *** N1c***                                           ***-- Isolated tumor cells in 1--2 regional lymph nodes***

  N2                                                   Metastasis in 3--6 regional lymph nodes

  N3                                                   Metastasis in 7 or more regional lymph nodes

  N3a\                                                 -- Metastasis in 7--15 regional lymph nodes\
  N3b                                                  -- Metastasis in 16 or more regional lymph nodes

  *** LC-N0-N3[\*\*](#tf3-2){ref-type="table-fn"}***   ***Intramural carcinomatosis of the lymph vessels from the submucosa and/or muscularis propria, regardless of the status of the lymph nodes***

  M0                                                   No distant metastases

  M1                                                   Distant metastases

  *** M1a***\                                          ***-- Metastasis in one or more distant lymph nodes or skip metastasis***\
  *** M1b***\                                          ***-- metastasis in one organ[\*\*\*](#tf3-3){ref-type="table-fn"}***\
  *** M1c***                                           ***-- metastasis in multiple organs[\*\*\*\*](#tf3-4){ref-type="table-fn"}***
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Micrometastasis refers to metastasis greater than 0.2 mm but smaller than 2 mm;

it is only reported for tumors with invasion limited to the mucosa, without direct invasion of the submucosa (pT1a);

in case of bone metastases, solitary metastasis;

in case of bone metastases, multicentric metastasis. LC -- lymphatic carcinomatosis, m -- mucosa, M -- distant metastasis, N -- regional lymph nodes, sm -- submucosa, T -- depth of infiltration of the primary tumor.

In our material, 7 of the 29 patients presented angiolymphatic invasion. From them, extended intramural carcinomatosis of the lymph vessels was seen in 1 patient who died 2 months after surgery. Because angio-lymphatic invasion is a significant prognostic parameter for patients with EGC \[[@cit0002], [@cit0014]--[@cit0019]\] it should be separately described in the pathologic reports of EGC ([Table III](#t0003){ref-type="table"}).

The adequate postoperative therapy of patients with EGC may also be influenced by a staging system specifically adapted for EGC. At the moment, according to the National Comprehensive Cancer Network (NCCN) guidelines version 3.2015, only postoperative follow-up is recommended for patients diagnosed with pT1N0 stage gastric cancer who underwent surgery, independently from other parameters, except the resection margins \[[@cit0020]\]. According to the European guidelines developed by the European Societies of Medical Oncology (ESMO), Surgical Oncology (ESSO), and Radiotherapy and Oncology (ESTRO), endoscopic resection is recommended for pT1N0 tumors smaller than 2 cm and preoperative chemotherapy is advised for the other cases. However, angiolymphatic invasion is not taken into account for the postoperative evaluation and surveillance, and the latest update was done in 2014 \[[@cit0021]\].

Another parameter that should be attentively examined in patients with EGC is the tumor multifocality or multicentricity. This characteristic was especially observed in hereditary diffuse gastric cancers \[[@cit0022]\], but acquired diffuse cancers can also have a multicentric aspect, being known as "carcinomas with intraepithelial pagetoid onset" \[[@cit0019]\]. Because the intramucosal foci are difficult to detect endoscopically \[[@cit0019], [@cit0022]\], description of multifocality in the histopathological report is a valuable parameter for endoscopic follow-up of patients who have undergone endoscopic resection or subtotal gastrectomy.

Regarding the immunoprofile, loss of E-cadherin, considered as an indicator of tumor progression \[[@cit0023]\], was seen in only one signet ring cell EGC at an early onset. The angiogenic activity was proved to be intense in half of the cases diagnosed in early stages. All of the COX-2 positive cases displayed high microvessel density. This aspect could support the possible prophylactic role of standard doses of anti-COX-2 substances, including aspirin, in reducing the overall cancer incidence in at least 3-year users. Long-term use is indicated to be prescribed after *Helicobacter pylori* eradication \[[@cit0024]\]. Moreover, in our material, 2 of the 4 tumors from the proximal stomach showed COX-2 but not HER-2 positivity (cases no. 16 and 19); neither of them was associated with intestinal metaplasia. This aspect could also sustain the role of anti-COX-2 substances in preventing gastric and/or esophageal carcinogenesis but not association of nonsteroidal anti-inflammatory drugs with a decreased risk of Barrett esophagus \[[@cit0024], [@cit0025]\]. Long-term use of anti-COX-2 substances could have a protective role for the gastric mucosa. On the other hand, non-Barrett related advanced tumors of the gastro-esophageal junction seem to not respond to trastuzumab. It is also worth noting that HER-2 positivity, shown by more than 25% of the EGC cases \[[@cit0005], [@cit0008]\], as well as the p53 index did not prove to indicate higher aggressiveness in EGC, as described in the advanced stages \[[@cit0005]\].

The clinical importance of angiogenesis is also sustained by magnifying endoscopy with narrow-band imaging used for diagnosis of EGC. This method proved that more than 90% of patients with EGC present irregular microvascular patterns referring to dilation or variation in diameter or shape and about one third of them show microvessel tortuosity \[[@cit0018]\]. Examining microvessel density and the morphological aspect could provide diagnostic and prognostic parameters for patients with EGC. Moreover, the highly angiogenic potential should be used as a therapeutic indicator, VEGF having pro-angiogenic and pro-inflammatory properties combined with its capacity for enhancing free radical generation \[[@cit0026]\].

Based on our results and literature data, we propose adapting the existent WHO/AJCC pTNM staging system used for GC \[[@cit0002], [@cit0003]\] to be specifically used for EGC ([Table III](#t0003){ref-type="table"}). This is a preliminary proposal, based on the findings of this study but also the daily experience of the five Professors in Pathology from Romania, Poland, Hungary, and Japan, which should be amended in the future.

The main weak point of the study is the small number of analyzed cases, which does not allow a detailed statistical analysis. However, the obtained results highlight the aggressiveness of EGC, which can be associated not only with the multifocal aspect, aberrant lymphatic flow, and skip metastasis but also with localization in the proximal stomach, independently from the microsatellite status, HER-2, E-cadherin, p53, or Ki67 expression. The angiogenic pattern could be used as a therapeutic target of EGC.
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